Regulation of experimental autoimmune encephalomyelitis with insulin- like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF- 1/IGFBP3)

Journal of Clinical Investigation

Volumn 101, Issue 8, 1998, Pages 1797-1804

  Lovett Racke, Amy E ^a   Bittner, Patrice ^a   Cross, Anne H ^a   Carlino, Joseph A ^a,b   Racke, Michael K ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Autoimmunity; Growth factors; Multiple sclerosis; Neuroimmunology

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN 3;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RELAPSE;

EID: 0032523210     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI1486     Document Type: Article

References (41)

1. Martin, R., H.F. McFarland, and D.E. McFarlin. 1992. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10:153-187.
2. Pettinelli, C.B., and D.E. McFarlin. 1981. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1 + 2-lymphocytes. J. Immunol. 127:1420-1423.
3. Racke, M.K., S. Dhib-Jalbut, B. Cannella, P.S. Albert, C.S. Raine, and D.E. McFarlin. 1991. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-ß1. J. Immunol. 146:3012-3017.
4. Racke, M.K., A. Bonomo, D.E. Scott, B. Cannella, A. Levine, C.S. Raine, E.M. Shevach, and M. Rocken. 1994. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 180:1961-1966.
5. Acha-Orbea, H., D.J. Mitchell, L. Timmerman, D.C. Wraith, G.S. Tausch, M.K. Waldor, S.S. Zamvil, H.O. McDevitt, and L. Steinman. 1988. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell. 54:263-273.
6. Urban, J.L., V. Kumar, D.H. Kono, C. Gomez, S.J. Horvath, J. Clayton, D.G. Ando, E.E. Sercarz, and L. Hood. 1988. Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy. Cell. 54:577-592.
7. Vandenbark, A.A., G. Hashim, and H. Offner. 1989. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental allergic encephalomyelitis. Nature. 341:541-544.
8. Howell, M.D., S.T. Winters, T. Olee, H.C. Powell, D.J. Carlo, and S.W. Brostoff. 1989. Vaccination against experimental allergic encephalomyelitis with T cell receptors peptides. Science. 246:668-670.
9. Brocke, S., K. Gijbels, M. Allegretta, I. Ferber, C. Piercy, T. Blankenstein, R. Martin, U. Utz, N. Karin, D. Mitchell, et al. 1996. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature. 379:343-346.
10. Cohick, W.S., and D.R. Clemmons. 1993. The insulin-like growth factors. Annu. Rev. Physiol. 55:131-153.
11. Leroith, D. 1997. Insulin-like growth factors. New Engl. J. Med. 336: 633-640.
12. Mozell, R.L., and F.A. McMorris. 1991. Insulin-like growth factor I stimulates oligodendrocyte development and myelination in rat brain aggregate cultures. J. Neurosci. Res. 30:382-390.
13. McMorris, F.A., T.M. Smith, S. DeSalvo, and R.W. Furlanetto. 1986. Insulin-like growth factor I/somatomedin C: a potent inducer of oligodendrocyte development. Proc. Natl. Acad. Sci. USA. 83:822-826.
14. Roth, G.A., V.H. Jorgensen, and M.B. Bornstein. 1985. Effect of insulin, proinsulin and pancreatic extract on myelination and remyelination in organotypic nerve tissue in culture. J. Neurol. Sci. 71:339-350.
15. Beck, K.D., L. Powell-Braxton, H.-R. Widmer, J. Valverde, and F. Hefti. 1995. Igf1 gene disruption results in reduced brain size. CNS hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons. Neuron. 14:717-730.
16. Carson, M.J., R.R. Behringer, R.L. Brinster, and F.A. McMorris. 1993. Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice. Neuron. 10:729-740.
17. Komoly, S., L.D. Hudson, H.deF. Webster, and C.A. Bondy. 1992. Insulin-like growth factor I gene expression is induced in astrocytes during experimental demyelination. Proc. Natl. Acad. Sci. USA. 89:1894-1898.
18. Liu, X., D.-L. Yao, and H.deF. Webster. 1995. Insulin-like growth factor I treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune encephalomyelitis. Multiple Sclerosis. 1:2-9.
19. Liu, X., D.-L. Yao, C.A. Bondy, M. Brenner, L.D. Hudson, J. Zhou, and H.deF. Wehster. 1994. Astrocytes express insulin-like growth factor-I (IGF-I) and its binding protein. IGFBP-2. during demyelination induced by experimental autoimmune encephalomyelitis. Mol. Cell. Neurosci. 5:418-430.
20. Yao, D.-L., X. Liu, L.D. Hudson, and H.deF. Webster. 1995. Insulin-like growth factor I treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA. 92:6190-6194.
21. Yao, D.-L., N.R. West, C.A. Bondy, M. Brenner, L.D. Hudson, J. Zhou, G.H. Collins, and H.deF. Webster. 1995. Cryogenic spinal cord injury induces astrocytic gene expression of insulin-like growth factor I and insulin-like growth factor binding protein 2 during myelin regeneration. J. Neurosci. Res. 40:647-659.
22. Adams, S., J. Moore, S. Chu, C. Bagi, L. DeLeon, C. Liu, D. Schmidt, and A. Sommer. 1995. Pharmacokinetics and bioavailability of hIGF-I/IGFBP-3 in the rat and monkey. Prog. Growth Factor Res. 6:347-356.
23. Kolaczynski, J.W., and J.F. Caro. 1994. Insulin-like growth factor-1 therapy in diabetes: physiologic basis, clinical benefits, and risks. Ann. Int. Med. 120:47-55.
24. Lewis, M.E., N.T. Neff, P.C. Contreras, D.B. Stong, R.W. Oppenheim, P.E. Grebow, and J.L. Vaught. 1993. Insulin-like growth factor-1: potential for treatment of motor neuronal disorders. Exp. Neurol. 124:73-88.
25. Deibler, G.E., R.E. Martenson, and M.W. Kies. 1972. Large scale preparation of myelin basic protein from central nervous system tissue of several mammalian species. Prep. Biochem. 2:139-165.
26. Sommer, A., C.A. Maack, S.K. Spratt, D. Mascarenhas, T.J. Tressel, E.T. Rhodes, R. Lee, M. Roumans, G.P. Tatsuno, J.A. Flynn, et al. 1991. Molecular genetics and actions of recombinant insulin-like growth factor binding protein-3. In Modern Concepts of Insulin-Like Growth Factors. E.M. Spencer, editor. Elsevier,New York. 715-728.
27. Lindsey, J.W., and L. Steinman. 1993. Competitive PCR quantification of CD4, CD8, ICAM-1, VCAM-1, and MHC class II mRNA in the central nervous system during development and resolution of experimental allergic encephalomyelitis. J. Neuroimmunol. 48:227-234.
28. Svetic, A., F.D. Finkelman, Y.C. Jian, C.W. Dieffenbach, D.E. Scott, K.F. McCarthy, A.D. Steinberg, and W.C. Gause. 1991. Cytokine gene expression after in vivo primary immunization with goat antibody to mouse IgD antibody. J. Immunol. 147:2391-2397.
29. Cross, A.H., T.J. Girard, K.S. Giacoletton, R.J. Evans, R.M. Keeling, R.F. Lin, J.L. Trotter, and R.W. Karr. 1995. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J. Clin. Invest. 95:2783-2789.
30. Moore, G.R.W., U. Traugott, M. Farooq, and C.S. Raine. 1984. Experimental autoimmune encephalomyelitis: augmentation of demyelination by different myelin lipids. Lab. Invest. 51:416-424.
31. Morrison, D.F. 1976. Multivariate Statistical Methods. McGraw-Hill, New York. 128-141.
32. Clark, R., J. Strasser, S. McCabe, K. Robbins, and P. Jardieu. 1993. Insulin-like growth factor-1 stimulation of lymphopoiesis. J Clin. Invest. 92:540-548.
33. Tapson, V.F., M. Boni-Schnetzler, P.P. Pilch, D.M. Center, and J.S. Berman. 1988. Structural and functional characterization of the human T lymphocyte receptor for insulin-like growth factor I in vitro. J. Clin. Invest. 82:950-957.
34. Reinhardt, R.R., and C.A. Bondy. 1994. Insulin-like growth factors cross the blood-brain barrier. Endocrinology. 135:1753-1761.
35. Pell, J.M., H.C. Flick-Smith, S. Dye, and R.A. Hill. 1995. Further characterization of an IGF-1 enhancing antibody: actions on IGF-1-induced hypoglycaemia and interaction with the analogue LR3IGF-1. Prog. Growth Factor Res. 6:367-375.
36. Hill, R.A., H.C. Flick-Smith, S. Dye, and J.M. Pell. 1997. Actions of an IGF-1-enhancing antibody on IGF-1 pharmacokinetics and tissue distribution: increased IGF-1 bioavailability. J. Endocrinol. 152:123-130.
37. Finkelman, F.D., K.B. Madden, S.C. Morris, J.M. Holmes, N. Boiani, I.M. Katona, and C.R. Maliszewski. 1993. Anti-cytokine antibodies as carrier proteins: prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J. Immunol. 151:1235-1244.
38. Reder, A.T., M. Thapar, and M.A. Jensen. 1994. A reduction in serum glucocorticoids provokes experimental allergic encephalomyelitis: implications for treatment of inflammatory brain disease. Neurology. 44:2289-2294.
39. Lehmann, P.V., T. Forsthuber, D. Miller, and E.E. Sercarz. 1992. Spreading of T cell autoimmunity to cryptic determinants of an autoantigen. Nature. 358:155-157.
40. Baron, J.L., J.A. Madri, N.H. Ruddle, G. Hashim, and C.A. Janeway, Jr. 1993. Surface expression of α4 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. 177:57-68.
41. Cannella, B., A.H. Cross, and C.S. Raine. 1990. Upregulation and coexpression of adhesion molecules correlate with relapsing autoimmune demyelination in the central nervous system. J. Exp. Med. 172:1521-1524.